| Protocol |
Title |
Status |
Contact |
| 103760 |
A Randomized Phase III Trial of Preoperative Compared to Post Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases |
OPEN TO ACCRUAL |
 |
| 103514 |
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE 102) |
OPEN TO ACCRUAL |
|
| 103749 |
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
OPEN TO ACCRUAL |
|
| 103518 |
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF ß Antagonist/IL 15 Protein Complex, for Advanced Pancreatic Cancer |
OPEN TO ACCRUAL |
|
| 103392 |
A Phase 1/2 Study of NM21 1480 (Anti PDL 1/Anti 4 1BB/Anti HSA Tri Specific Antibody) in Adult Patients With Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 103699 |
PHASE III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First Line Platinum Based Chemotherapy in Patients With Metastatic Urothelial Cancer |
OPEN TO ACCRUAL |
|
| 103491 |
A Phase II Open Label, Study of IMMU 132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti PD 1/PD L1 Based Immunotherapy |
OPEN TO ACCRUAL |
|
| 103415 |
PSMAddition: An International Prospective Open label, Randomized, Phase III Study comparing 177Lu PSMA 617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
OPEN TO ACCRUAL |
|
| 103714 |
A Phase II Randomized Trial of Olaparib (NSC 747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer. |
OPEN TO ACCRUAL |
|
| 103472 |
T Reg Function Changes: A Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer |
OPEN TO ACCRUAL |
|
| 103715 |
A Randomized Phase II Study Comparing Single Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi Arm Trial for Women with Recurrent or Persistent Endometrial Cancer |
OPEN TO ACCRUAL |
|
| 103681 |
Phase III Trial of Immunotherapy Based Combination Therapy With or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (PROBE TRIAL) |
OPEN TO ACCRUAL |
|
| 103668 |
Phase III Trial of Salvage Stereotatic Radiosurgery (SRS) or SRS + Hippocampalacodiant Whole Brain Radiotherapy (HA WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brian Metastasis Velocity =4 Brian Metastases/ Year |
OPEN TO ACCRUAL |
|
| 103488 |
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B Acute Lymphoblastic Leukemia (B ALL) |
OPEN TO ACCRUAL |
|
| 103722 |
Melanoma Margins Trial (MelMarT II): A Phase III, Multi Centre, Multi National Randomized Control Trial investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma |
OPEN TO ACCRUAL |
|
| 103560 |
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors |
OPEN TO ACCRUAL |
|
| 103645 |
A Randomized Phase II Trial of Triplet Therapy (A PDL1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab |
OPEN TO ACCRUAL |
|
| 103627 |
Randomized Phase II/III Trial of Radiation with High Dose Cisplatin (100mg/m2) Every Three Weeks Versus Radiation with Low Dose Cisplatin (40mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
OPEN TO ACCRUAL |
|
| 103632 |
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD L1 Negative, Advanced Non Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103664 |
Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post Prostatectomy Biochemical Recurrence (INDICATE) |
OPEN TO ACCRUAL |
|